<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="108.00-Skin-Childhood">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>108.00 Skin Disorders - Childhood | Disability | SSA</title>
 
    <!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"SJ-86d8640c-26e8-4549-b53c-eceab2da1d48","rua.cook":"true","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n="false"=="true"?1:0,t="cookiepresent",a="im6jsaqx2s4262inlk7q-f-4e251da48-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":22,"ak.ipv":4,"ak.proto":"h3","ak.rid":"1a09ab46","ak.r":49961,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":62156,"ak.gh":"23.210.6.52","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762482879","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==0hzaWJT2u/AmKedodl+tT8n9oRbuVLdIv17dPtbaV9tBYEG0U5TWugzLTM8Ae9kbtx9+sf2+cPX+doCE61PvHG6JwOnfgoIn9X8OPygdXpHIDmItwNBzQhP4k0qYbWruJhLCTfgwqQIFJcv/ifJLA6YILrgqPEjIT6hV550l/xtpYd33Qqvf5RWYJIp5Oi1zBCA6EwMHXIaqTvrLn5VYBHs973aiBblw+HsA0g/JXm/OSOPcg5aWrGBYlUyLOzFWO5iN+sLX4EGZm3sTTfA6JB6THPYDjWQCEsgwoap/kSr1D4nOMjZy3BBGHM3PDwY73bO71Jz4eyiMXMT84wkZ/mUkkHkBkUen0jxjvOGhCAeZ8VlZViAzpXMoXRaZ1C540aFTG6pyFF1V2Fqwna3BaId24PTTbiSwupLAhyKoHJQ=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/108.00-Skin-Childhood.htm#108_00"><meta property="og:title" content="108.00 Skin Disorders - Childhood | Disability | SSA"><meta property="og:description" content="108.00-Skin-Childhood"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2>
       </div>
    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="ChildhoodListings.htm">Listing of Impairments - Child Listings (Part B)</a></li> 
    <li aria-current="page">108.00 Skin Disorders - Childhood</li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

    <h2><span><b>
    Disability Evaluation Under Social Security<br>
    <br>
    108.00 Skin Disorders - Childhood<br>
    &nbsp;
</b></span></h2>

                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
                        <article class="cell w-100 m-w-20">

                            <u><b>Section</b></u><br><br>

                            <p>
                                <a href="#108_01" title=" 108.01 Category of Impairments, Skin Disorders">
                                    <b>108.01</b><br>
                                    Category of Impairments, Skin Disorders
                                </a>
                            </p>
                            <p>
                                <a href="#108_07" title=" 108.07 Genetic photosensitivity disorders">
                                    <b>108.07</b><br>Genetic photosensitivity disorders
                                </a>
                            </p>
                            <p>
                                <a href="#108_08" title=" 108.08 Burns">
                                    <b>108.08</b><br>
                                    Burns
                                </a>
                            </p>
                            <p>
                                <a href="#108_09" title=" 108.09 Chronic conditions of the skin or mucous membranes ">
                                    <b>108.09</b><br>
                                    Chronic conditions of the skin or mucous membranes
                                </a><br>
                            </p>
                        </article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
                    <article class="cell w-100 m-w-80">

                        <p id="108_00"><u><b>108.00 Skin Disorders</b></u></p>
                        <p id="108_00A">
                            <strong>A.</strong> <i>Which skin disorders do we evaluate under these listings? </i>
                            We use these listings to evaluate skin disorders that result from hereditary, congenital, or acquired pathological processes. 
                            We evaluate genetic photosensitivity disorders (<a href="#108_07" title="Section 108.07">108.07</a>), burns (<a href="#108_08" title="Section 108.08">108.08</a>), 
                            and chronic conditions of the skin or mucous membranes such as ichthyosis, bullous disease, dermatitis, psoriasis, 
                            and hidradenitis suppurativa (<a href="#108_09" title="Section 108.09">108.09</a>) under these listings.
                        </p>
                        <p id="108_00B">
                            <strong>B.</strong> <i>What are our definitions for the following terms used in this body system? </i>
                        </p>
                        <p id="108_00B1">1. <em>Assistive device(s): </em> An assistive device, for the purposes of these listings, is any device used to improve stability, dexterity, or mobility. An assistive device can be hand-held, such as a cane(s), a crutch(es), or a walker; used in a seated position, such as a wheelchair, rollator, or power operated vehicle; or worn, such as a prosthesis or an orthosis. </p>
                        <p id="108_00B2">
                            2. <em>Chronic skin lesions:</em> Chronic skin lesions can have recurrent exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>).
                            They can occur despite prescribed medical treatment. These chronic skin lesions can develop on any part of your body, including upper extremities, lower extremities, palms of your hands,
                            soles of your feet, the perineum, inguinal (groin) region, and axillae (underarms).
                            Chronic skin lesions may result in functional limitations as described in <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>.
                        </p>
                        <p id="108_00B3">
                            3. <em>Contractures:</em> Contractures are permanent fibrous scar tissue resulting in tightening and thickening of skin that prevents normal movement of the damaged area. 
                            They can develop on any part of your musculoskeletal system, including upper extremities, lower extremities, palms of your hands, soles of your feet, the perineum, inguinal (groin) region, 
                            and axillae (underarms). Contractures may result in functional limitations as described in <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>.</p>
                        <p id="108_00B4">
                            4. <em>Documented medical need:</em> When we use the term "documented medical need," we mean that there is evidence
                            (see §<a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0913.htm" target="_blank" title="Code of Federal Regulations section 416.913">416.913</a> of this chapter)
                            from your medical source(s) in the medical record that supports your need for an assistive device (see <a href="#108_00B1" title="Section 108.00 - Subsection B1">108.00B1</a>) for a continuous period of at least 12 months.
                            The evidence must include documentation from your medical source(s) describing any limitation(s) in your upper or lower extremity functioning that supports your need for the assistive device
                            and describing the circumstances for which you need it. The evidence does not have to include a specific prescription for the device.
                        </p>
                        <p id="108_00B5">5. <em>Fine and gross movements: </em>Fine movements, for the purposes of these listings, involve use of your wrists, hands, and fingers; such movements include picking, pinching, manipulating, and fingering. Gross movements involve use of your shoulders, upper arms, forearms, and hands; such movements include handling, gripping, grasping, holding, turning, and reaching. Gross movements also include exertional activities such as lifting, carrying, pushing, and pulling. Evaluation of fine and gross movements is dependent on your age. </p>
                        <p id="108_00B6">6. <em>Surgical management: </em> For the purposes of these listings, surgical management includes the surgery(ies) itself, as well as various post-surgical procedures, surgical complications, infections or other medical complications, related illnesses, or related treatments that delay a person's attainment of maximum benefit from surgery.</p>
                        <p id="108_00B7">7. <em>Exacerbation: </em> For the purposes of these listings, exacerbation means an increase in the signs or symptoms of the skin disorder. Exacerbation may also be referred to as flare, flare-up, or worsening of the skin disorder.</p>
                        <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>

                        <p id="108_00C">
                            <strong>C.</strong> <i>What evidence do we need to evaluate your skin disorder?</i>
                        </p>
                        <p id="108_00C1">
                            1. To establish the presence of a skin disorder as a medically determinable impairment, we need objective medical evidence from an acceptable medical source (AMS) who has examined you for the disorder.
                        </p>

                        <p id="108_00C2">
                            2. We will make every reasonable effort to obtain your medical history, treatment records, and relevant laboratory findings, but we will not purchase genetic testing.
                        </p>
                        <p id="108_00C3">
                            3. When we evaluate the presence and severity of your skin disorder(s), we generally need information regarding:
                        </p>
                        <p id="108_00C3a">
                            a. The onset, duration, and frequency of exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>);
                        </p>
                        <p id="108_00C3b">
                            b. The prognosis of your skin disorder;
                        </p>
                        <p id="108_00C3c">
                            c. The location, size, and appearance of lesions and contractures;
                        </p>
                        <p id="108_00C3d">
                            d. Any available history of familial incidence;
                        </p>
                        <p id="108_00C3e">
                            e. Your exposure to toxins, allergens or irritants; seasonal variations; and stress factors;
                        </p>
                        <p id="108_00C3f">
                            f. Your ability to function outside of a highly protective environment (see <a href="#108_00E4" title="Section 108.00 - Subsection E4">108.00E4</a>);
                        </p>
                        <p id="108_00C3g">
                            g. Laboratory findings (for example, a biopsy obtained independently of Social Security disability evaluation or results of blood tests);
                        </p>
                        <p id="108_00C3h">
                            h. Evidence from other medically acceptable methods consistent with the prevailing state of medical knowledge and clinical practice; and
                        </p>
                        <p id="108_00C3i">
                            i. Statements you or others make about your disorder(s), your restrictions, and your daily activities.
                        </p>
                        <p id="108_00D">
                            <strong>D.</strong> <i>How do we evaluate the severity of skin disorders?</i>
                        </p>
                        <p id="108_00D1">
                            1. <em>General. </em>
                            We evaluate the severity of skin disorders based on the site(s) of your chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>)
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>), functional limitations caused by your signs and symptoms
                            (including pain) (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>), and how your prescribed treatment affects you.
                            We consider the frequency and severity of your exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>), how quickly they resolve,
                            and how you function between exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>),
                            to determine whether your skin disorder meets or medically equals a listing (see <a href="#108_00D3" title="Section 108.00 - Subsection D3">108.00D3</a>).
                            If there is no record of ongoing medical treatment for your disorder, we will follow the guidelines in <a href="#108_00D6" title="Section 108.00 - Subsection D6">108.00D6</a>.
                            We will determine the extent and kinds of evidence we need from medical and non-medical sources based on the individual facts about your disorder.
                            For our basic rules on evidence, see §§ <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0912.htm" target="_blank" title="Code of Federal Regulations section 416.912">416.912</a>,
                            <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0913.htm" target="_blank" title="Code of Federal Regulations section 416.913">416.913</a>,
                            and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920b.htm" target="_blank" title="Code of Federal Regulations section 416.920b">416.920b</a> of this chapter.
                            For our rules on evaluating your symptoms, see § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0929.htm" target="_blank" title="Code of Federal Regulations section 416.929">416.929</a> of this chapter.
                        </p>

                        <p id="108_00D2">
                            2.<em> Limitation(s) of physical functioning due to skin disorders.</em>
                        </p>
                        <p id="108_00D2a">
                            a. Skin disorders may be due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>),
                            and may cause pain or restrict movement, which can limit your ability to initiate, sustain, and complete age-appropriate activities.
                            For example, skin lesions in the axilla may limit your ability to raise or reach with the affected arm, or lesions in the inguinal region may limit your ability to ambulate, sit, or lift and carry.
                            To evaluate your skin disorder(s) under <a href="#108_07B" title="Section 108.07 - Subsection B">108.07B</a>, <a href="#108_08" title="Section 108.08">108.08</a>,
                            and <a href="#108_09" title="Section 108.09">108.09</a>, we require medically documented evidence of physical limitation(s) of functioning related to your disorder.
                            The decrease in physical function must have lasted, or can be expected to last, for a continuous period of at least 12 months
                            (see § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0909.htm" target="_blank" title="Code of Federal Regulations section 416.909">416.909</a> of this chapter).
                            Xeroderma pigmentosum is the only skin disorder that does not include functional criteria because the characteristics
                            and severity of the disorder itself are sufficient to meet the criteria in <a href="#108_07A" title="Section 108.07 - Subsection A">108.07A</a>.
                        </p>
                        <p id="108_00D2b">
                           b. The functional criteria require impairment-related physical limitations in using upper or lower extremities that have lasted, or can be expected to last, for a continuous period of at least 12 months, medically documented by one of the following:
                        </p>
                        <p id="108_00D2bi">
                            (i) Inability to use both upper extremities to the extent that neither can be used to independently initiate, sustain, 
                            and complete age-appropriate activities involving fine and gross movements (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>); or
                        </p>
                        <p id="108_00D2bii">
                            (ii) Inability to use one upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>), and a documented medical need 
                            (see <a href="#108_00B4" title="Section 108.00 - Subsection B4">108.00B4</a>) for an assistive device (see <a href="#108_00B1" title="Section 108.00 - Subsection B1">108.00B1</a>) that requires the use of the other upper extremity; or
                        </p>
                        <p id="108_00D2biii">
                            (iii) Inability to stand up from a seated position and maintain an upright position to the extent needed to independently initiate, sustain, 
                            and complete age-appropriate activities due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting at least two extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region); or
                        </p>
                        <p id="108_00D2biv">
                            (iv) Inability to maintain an upright position while standing or walking to the extent needed to independently initiate, sustain, and complete age-appropriate activities due to chronic skin lesions 
                            (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting both lower extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region).
                        </p>
                        <p id="108_00D3">
                            3. <em>Frequency of exacerbations due to chronic skin lesions. </em>
                            A skin disorder resulting in chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) may have frequent exacerbations 
                            (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>) severe enough to meet a listing even if each individual skin lesion exacerbation 
                            (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>) did not last for an extended amount of time. We will consider the frequency, severity, 
                            and duration of skin lesion exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>), 
                            how quickly they resolve, and how you function in the time between skin lesion exacerbations (see <a href="#108_00B7" title="Section 108.00 - Subsection B7">108.00B7</a>), 
                            to determine whether your skin disorder meets or medically equals a listing.
                        </p>
                        <p id="108_00D4">
                            4. <em>Symptoms (including pain).</em>
                            Your symptoms may be an important factor in our determination of whether your skin disorder(s) meets or medically equals a listing.
                            We consider your symptoms only when you have a medically determinable impairment(s) that could reasonably be expected to produce the symptoms.
                            See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0929.htm" target="_blank" title="Code of Federal Regulations section 416.929">416.929</a> of this chapter.
                        </p>
                        <p id="108_00D5">
                            5. <em>Treatment.</em>
                        </p>
                        <p id="108_00D5a">
                            a. <em>General.</em>
                            Treatments for skin disorders may have beneficial or adverse effects, and responses to treatment vary from person to person. Your skin disorder's response to treatment may vary due to treatment resistance or side effects that can result in functional limitations. We will evaluate all of the effects of treatment (including surgical treatment, medications, and therapy) on the symptoms, signs, and laboratory findings of your skin disorder, and on your ability to function.
                        </p>
                        <p id="108_00D5b">
                           b. <em>Despite adherence to prescribed medical treatment for 3 months.</em>
                            Under <a href="#108_09" title="Section 108.09">108.09</a>, we require that your symptoms persist "despite adherence to prescribed medical treatment for 3 months." 
                            This requirement means that you must have taken prescribed medication(s) or followed other medical treatment prescribed by a medical source for 3 consecutive months. 
                            Treatment or effects of treatment may be temporary. In most cases, sufficient time must elapse to allow us to evaluate your response to treatment, including any side effects. 
                            For our purposes, “sufficient time” means a period of at least 3 months. 
                            If your treatment has not lasted for at least 3 months, we will follow the rules in <a href="#108_00D6a" title="Section 108.00 - Subsection D6a">108.00D6a</a>. 
                            The 3 months adherence to prescribed medical treatment must be within the period of at least 12 months that we use to evaluate severity.
                        </p>
                        <p id="108_00D5c">
                            c. <em>Treatment with PUVA (psoralen and ultraviolet A (UVA) light) or biologics. </em>
                            If you receive additional treatment with PUVA or biologics to treat your skin disorder(s), we will defer adjudication of your claim for 6 months from the start of treatment with PUVA or biologics to evaluate the effectiveness of these treatments unless we can make a fully favorable determination or decision on another basis.
                        </p>
                        <p id="108_00D6">
                            6. <em>No record of ongoing treatment.</em>
                        </p>
                        <p id="108_00D6a"> 
                            a. Despite having a skin disorder, you may not have received ongoing treatment, may have just begun treatment, may not have access to prescribed medical treatment,
                            or may not have an ongoing relationship with the medical community. In any of these situations, you will not have a longitudinal medical record for us to review when we evaluate your disorder.
                            In some instances, we may be able to assess the severity and duration of your skin disorder based on your medical record and current evidence alone.
                            We may ask you to attend a consultative examination to determine the severity and potential duration of your skin disorder
                            (see § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0919a.htm" target="_blank" title="Code of Federal Regulations section 416.919a">416.919a</a> of this chapter).
                        </p>
                        <p id="108_00D6b">
                            b. If, for any reason, you have not received treatment, your skin disorder cannot meet the criteria for <a href="#108_09" title="Section 108.09">108.09</a>. 
                            If the information in your case record is not sufficient to show that you have a skin disorder that meets the criteria of one of the skin disorders listings, 
                            we will follow the rules in <a href="#108_00I" title="Section 108.00 - Subsection I">108.00I</a>.
                        </p>
                        <p id="108_00E"> 
                            <strong>E.</strong> <i>How do we evaluate genetic photosensitivity disorders under  <a href="#108_07" title="Section 108.07">108.07</a>?</i>
                            Genetic photosensitivity disorders are disorders of the skin caused by an increase in the sensitivity of the skin to sources of ultraviolet light, including sunlight.
                        </p>
                        <p id="108_00E1">
                            1. <em>Xeroderma pigmentosum (XP)(<a href="#108_07A" title="Section 108.07 - Subsection A">108.07A</a>). </em>
                            XP is a genetic photosensitivity disorder with lifelong hypersensitivity to all forms of ultraviolet light. 
                            Laboratory testing confirms the diagnosis by documenting abnormalities in the body's ability to repair DNA (deoxyribonucleic acid) mutations after ultraviolet light exposure. 
                            Your skin disorder meets the requirements of <a href="#108_07A" title="Section 108.07 - Subsection A">108.07A</a> if you have clinical and laboratory findings supporting a diagnosis of XP 
                            (see <a href="#108_00E3" title="Section 108.00 - Subsection E3">108.00E3</a>).
                        </p>

                        <p id="108_00E2">
                            2.<em> Other genetic photosensitivity disorders (<a href="#108_07B" title="Section 108.07 - Subsection B">108.07B</a>).</em>
                            The effects of other genetic photosensitivity disorders may vary and may not persist over time. To meet the requirements of <a href="#108_07B" title="Section 108.07 - Subsection B">108.07B</a>, 
                            a genetic photosensitivity disorder other than XP must be established by clinical and laboratory findings 
                            (see <a href="#108_00C" title="Section 108.00 - Subsection C">108.00C</a>) and must result either in chronic skin lesions (<a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) that result in functional limitations (<a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>), 
                            or must result in the inability to function outside of a highly protective environment (see <a href="#108_00E4" title="Section 108.00 - Subsection E4">108.00E4</a>). 
                            Some genetic photosensitivity disorders can have very serious effects on other body systems, especially special senses and speech, neurological, mental, and cancer. 
                            We will evaluate your disorder(s) under the listings in 
                            <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>, 
                            <a href="111.00-Neurological-Childhood.htm#111_00" title="111.00 Neurological - Childhood Page, Section 111.00" target="_blank">111.00</a>, 
                            <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>, 
                            or <a href="113.00-NeoplasticDiseases-Malignant-Childhood.htm#113_00" target="_blank" title="113.00 Cancer-Childhood Page, Section 113.00">113.00</a>, as appropriate.
                        </p>
                        <p id="108_00E3">
                            3.<em> What evidence do we need to document that you have XP or another genetic photosensitivity disorder? </em>
                            We will make a reasonable effort to obtain evidence of your disorder(s), but we will not purchase genetic testing. When the results of genetic tests are part of the existing evidence in your case record, 
                            we will evaluate the test results with all other relevant evidence. We need the following clinical and laboratory findings to document that you have XP or another genetic photosensitivity disorder:
                        </p>
                        <p id="108_00E3a">
                            a. A laboratory report of a definitive genetic test documenting appropriate chromosomal changes, including abnormal DNA repair or another DNA abnormality specific to your type of photosensitivity disorder, signed by an AMS; or
                        </p>
                        <p id="108_00E3b">
                            b. A laboratory report of a definitive test that is not signed by an AMS, and a report from an AMS stating that you have undergone definitive genetic laboratory studies documenting appropriate chromosomal changes, including abnormal DNA repair or another DNA abnormality specific to your type of photosensitivity disorder; or
                        </p>
                        <p id="108_00E3c">
                            c. If we do not have a laboratory report of a definitive test, we need documentation from an AMS that an appropriate laboratory analysis or other diagnostic method(s) confirms a positive diagnosis of your skin disorder. This documentation must state that you had the appropriate definitive laboratory test(s) for diagnosing your disorder and provide the results, or explain how another diagnostic method(s), consistent with the prevailing state of medical knowledge and clinical practice, established your diagnosis.
                        </p>
                        <p id="108_00E4">
                            4.<em> Inability to function outside of a highly protective environment </em>
                            means that you must avoid exposure to ultraviolet light (including sunlight passing through windows and light from similar unshielded light sources), wear protective clothing and eyeglasses, and use opaque broad-spectrum sunscreens in order to avoid skin cancer or other serious effects.
                        </p>
                        <p id="108_00F">
                            <strong>F.</strong> <i>How do we evaluate burns under <a href="#108_08" title="Section 108.08">108.08</a>? </i>
                        </p>
                        <p id="108_00F1">
                            1. Electrical, chemical, or thermal burns frequently affect other body systems; for example, musculoskeletal, special senses and speech, respiratory, cardiovascular, genitourinary, neurological, or mental. 
                            We evaluate burns in the same way we evaluate other disorders that can affect the skin and other body systems, using the listing for the predominant feature of your disorder. 
                            For example, if your soft tissue injuries resulting from burns are under surgical management (as defined in <a href="#108_00B6" title="Section 108.00 - Subsection B6">108.00B6</a>), 
                            we will evaluate your disorder under the listings in <a href="101.00-Musculoskeletal-Childhood.htm#101_00" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00" target="_blank">101.00</a>.
                        </p>

                        <p id="108_00F2">
                            2. We evaluate burns resulting in chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) that have been documented by an AMS to have reached maximum therapeutic benefit 
                            and therefore are no longer receiving surgical management, under <a href="#108_08" title="Section 108.08">108.08</a>. 
                            To be disabling, these burns must result in functional limitation(s) 
                            (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>) that has lasted or can be expected to last for a continuous period of at least 12 months.
                        </p>
                        <p id="108_00G">
                            <strong>G.</strong> <i>How do we evaluate chronic conditions of the skin or mucous membranes under <a href="#108_09" title="Section 108.09">108.09</a>?  </i>
                            We evaluate skin disorders that result in chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) under <a href="#108_09" title="Section 108.09">108.09</a>. 
                            These disorders must result in chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) that continue to persist despite adherence to prescribed medical treatment for 3 months 
                            (see <a href="#108_00D5b" title="Section 108.00 - Subsection D5b">108.00D5b</a>) and cause functional limitations (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>). 
                            Examples of skin disorders evaluated under this listing are ichthyosis, bullous diseases (such as pemphigus, epidermolysis bullosa, and dermatitis herpetiformis), 
                            chronic skin infections, dermatitis, psoriasis, and hidradenitis suppurativa.
                        </p>
                        <p id="108_00H">
                            <strong>H.</strong> <i>How do we evaluate disorders in other body systems that affect the skin? </i>
                            When your disorder(s) in another body system affects your skin, we first evaluate the predominant feature of your disorder(s) under the appropriate body system. 
                            Examples of disorders in other body systems that affect the skin include the following:
                        </p>
                        <p id="108_00H1">
                            1. <em>Tuberous sclerosis.</em>
                            The predominant functionally limiting features of tuberous sclerosis are seizures and intellectual disorder or other mental disorders. 
                            We evaluate these features under the listings in <a href="111.00-Neurological-Childhood.htm#111_00" title="111.00 Neurological - Childhood Page, Section 111.00" target="_blank">111.00</a> 
                            or <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>, as appropriate.
                        </p>
                        <p id="108_00H2">
                            2. <em>Malignant tumors of the skin.</em>
                            Malignant tumors of the skin (for example, malignant melanomas) are cancers, or malignant neoplastic diseases, 
                            that we evaluate under the listings in <a href="113.00-NeoplasticDiseases-Malignant-Childhood.htm#113_00" target="_blank" title="113.00 Cancer-Childhood Page, Section 113.00">113.00</a>.
                        </p>
                        <p id="108_00H3">
                            3. <em>Immune system disorders.</em>
                            We evaluate skin manifestations of immune system disorders such as systemic lupus erythematosus, scleroderma, psoriasis, 
                            and human immunodeficiency virus (HIV) infection under the listings in <a href="114.00-Immune-Childhood.htm#114_00" target="_blank" title="114.00 Immune System Disorders - Childhood Page, Section 114.00">114.00</a>.
                        </p>

                        <p id="108_00H4">
                            4. <em>Head or facial disfigurement or deformity, and other physical deformities caused by skin disorders. </em>
                            A head or facial disfigurement or deformity may result in loss of your sight, hearing, speech, or ability to chew. In addition to head and facial disfigurement and deformity, 
                            other physical deformities may result in associated psychological problems (for example, depression). 
                            We evaluate the effects of head or facial disfigurement or deformity, or other physical deformities caused by skin disorders under the listings in 
                            <a href="101.00-Musculoskeletal-Childhood.htm#101_00" title="101.00 Musculoskeletal System - Childhood Page, Section 101.00" target="_blank">101.00</a>, 
                            <a href="102.00-SpecialSensesandSpeech-Childhood.htm#102_00" target="_blank" title="102.00 Special Senses and Speech - Childhood Page, Section 102.00">102.00</a>, 
                            <a href="105.00-Digestive-Childhood.htm#105_00" target="_blank" title="105.00 Digestive System - Childhood Page, Section 105.00">105.00</a>, 
                            or <a href="112.00-MentalDisorders-Childhood.htm#112_00" title="112.00 Mental Disorders - Childhood Page, Section 112.00" target="_blank">112.00</a>, as appropriate.
                        </p>
                        <p id="108_00H5">
                            5. <em>Porphyria.</em>
                            We evaluate erythropoietic protoporphyria under the listings in <a href="107.00-HematologicalDisorders-Childhood.htm#107_00" target="_blank" title="107.00 Hematological Disorders - Childhood Page, Section 107.00">107.00</a>.
                        </p>

                        <p id="108_00H6">
                            6. <em>Hemangiomas. </em>
                            We evaluate hemangiomas associated with thrombocytopenia and hemorrhage (for example, Kasabach-Merritt syndrome) 
                            involving coagulation defects under the listings in <a href="107.00-HematologicalDisorders-Childhood.htm#107_00" target="_blank" title="107.00 Hematological Disorders - Childhood Page, Section 107.00">107.00</a>. 
                            When hemangiomas impinge on vital structures or interfere with functioning, we evaluate their primary effects under the listings in the appropriate body system.
                        </p>
                        <p id="108_00I">
                            <strong>I.</strong> <i>How do we evaluate skin disorders that do not meet one of these listings? </i>
                        </p>
                        <p id="108_00I1">
                            1. These listings are only examples of common skin disorders that we consider severe enough to result in marked and severe limitations. If your impairment(s) does not meet the criteria of any of these listings, we must also consider whether you have an impairment(s) that satisfies the criteria of a listing in another body system.
                        </p>
                        <p id="108_00I2">
                            2. If you have a severe medically determinable impairment(s) that does not meet a listing, we will determine whether your impairment(s) medically equals a listing.
                            See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.926">416.926</a> of this chapter.
                            If your impairment(s) does not meet or medically equal a listing, we will also consider whether your impairment(s) functionally equals the listings.
                            See § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926a.htm" target="_blank" title="Code of Federal Regulations section 416.926a">416.926a</a> of this chapter.
                            We use the rules in § <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994a.htm" target="_blank" title="Code of Federal Regulations section 416.994a">416.994a</a>
                            of this chapter when we decide whether you continue to be disabled.
                        </p>
                        <p id="108_01">
                            <b>
                                108.01
                                Category of Impairments, Skin Disorders
                            </b>
                        </p>
                        <p id="108_02"><strong><em>108.02&nbsp; </em>[Reserved]</strong></p>
                        <p id="108_03"><strong><em>108.03&nbsp; </em>[Reserved]</strong></p>
                        <p id="108_04"><strong><em>108.04&nbsp; </em>[Reserved]</strong></p>
                        <p id="108_05"><strong><em>108.05&nbsp; </em>[Reserved]</strong></p>
                        <p id="108_06"><strong><em>108.06&nbsp; </em>[Reserved]</strong></p>
                        <p align="left" id="108_07">
                            <b>

                                108.07 <em>Genetic photosensitivity disorders, </em>
                            </b>established as described in <a href="#108_00E" title="Section 108.00 - Subsection E">108.00E</a>. The requirements of this listing are met if either paragraph A or paragraph B is satisfied.
                        </p>
                        <p id="108_07A">
                            <strong>A.</strong> Xeroderma pigmentosum (see <a href="#108_00E1" title="Section 108.00 - Subsection E1">108.00E1</a>).
                        </p>
                        <p>OR</p>
                        <p id="108_07B">
                           <strong>B.</strong> Other genetic photosensitivity disorders (see <a href="#108_00E2" title="Section 108.00 - Subsection E2">108.00E2</a>) with either 1 or 2:
                        </p>
                        <p id="108_07B1">
                            1. Chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures 
                            (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) that cause an inability to function outside of a highly protective environment 
                            (see <a href="#108_00E4" title="Section 108.00 - Subsection E4">108.00E4</a>); or
                        </p>
                        <p id="108_07B2">
                            2. Chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) causing chronic pain or other physical limitation(s) that result in impairment-related functional limitations 
                            (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>), as evidenced by:
                        </p>
                        <p id="108_07B2a">
                            a. Inability to use both upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>); or
                        </p>
                        <p id="108_07B2b">
                            b. Inability to use one upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>), and a documented medical need 
                            (see <a href="#108_00B4" title="Section 108.00 - Subsection B4">108.00B4</a>) for an assistive device 
                            (see <a href="#108_00B1" title="Section 108.00 - Subsection B1">108.00B1</a>) that requires the use of the other upper extremity; or
                        </p>
                        <p id="108_07B2c">
                            c. Inability to stand up from a seated position and maintain an upright position to the extent needed to independently initiate, sustain, 
                            and complete age-appropriate activities due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting at least two extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region); or
                        </p>
                        <p id="108_07B2d">
                            d. Inability to maintain an upright position while standing or walking to the extent needed to independently initiate, sustain, and complete age-appropriate activities due to chronic skin lesions 
                            (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) 
                            affecting both lower extremities (including when the limitations are due to involvement of the perineum or the inguinal region).
                        </p>
                        <p id="108_08">
                            <b> 108.08 <em>Burns </em></b>
                            (see <a href="#108_00F" title="Section 108.00 - Subsection F">108.00F</a>). 
                            Burns that do not require continuing surgical management (see <a href="#108_00B6" title="Section 108.00 - Subsection B6">108.00B6</a>), 
                            or that have been documented by an acceptable medical source to have reached maximum therapeutic benefit and are no longer receiving surgical management, 
                            resulting in chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) causing chronic pain 
                            or other physical limitation(s) that result in impairment-related functional limitations (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>), as evidenced by:
						</p>
                        <p id="108_08A">
                            <strong>A.</strong> 
                            Inability to use both upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>).
                        </p>
                        <p>OR</p>
                        <p id="108_08B">
                            <strong>B.</strong> 
                            Inability to use one upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>), and a documented medical need 
                            (see <a href="#108_00B4" title="Section 108.00 - Subsection B4">108.00B4</a>) for an assistive device (see <a href="#108_00B1" title="Section 108.00 - Subsection B1">108.00B1</a>) 
                            that requires the use of the other upper extremity.
                        </p>
                        <p>OR</p>
                        <p id="108_08C">
                            <strong>C.</strong> 
                            Inability to stand up from a seated position and maintain an upright position to the extent needed to independently initiate, sustain, 
                            and complete age-appropriate activities due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting at least two extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region).
                        </p>
                        <p>OR</p>
                        <p id="108_08D">
                            <strong>D.</strong> 
                            Inability to maintain an upright position while standing or walking to the extent needed to independently initiate, sustain, 
                            and complete age-appropriate activities due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting both lower extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region).
                        </p>
                        <p id="108_09">
                            <b> 108.09 <em> Chronic conditions of the skin or mucous membranes</em></b>
                            (see <a href="#108_00G" title="Section 108.00 - Subsection G">108.00G</a>) resulting in:
                        </p>
                        <p id="108_09A">
                            <strong>A.</strong> 
                            Chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) 
                            causing chronic pain or other physical limitation(s) that persist despite adherence to prescribed medical treatment for 3 months 
                            (see <a href="#108_00D5b" title="Section 108.00 - Subsection D5b">108.00D5b</a>).
                        </p>
                        <p>AND</p>
                        <p id="108_09B">
                            <strong>B.</strong> Impairment-related functional limitations (see <a href="#108_00D2" title="Section 108.00 - Subsection D2">108.00D2</a>) demonstrated by 1, 2, 3, or 4:
                        </p>
                        <p id="108_09B1">
                            1. Inability to use both upper extremities to the extent that neither can be used to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>); or
                        </p>
                        <p id="108_09B2">
                            2. Inability to use one upper extremity to independently initiate, sustain, and complete age-appropriate activities involving fine and gross movements 
                            (see <a href="#108_00B5" title="Section 108.00 - Subsection B5">108.00B5</a>) due to chronic skin lesions (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) 
                            or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>), and a documented medical need 
                            (see <a href="#108_00B4" title="Section 108.00 - Subsection B4">108.00B4</a>) for an assistive device (see <a href="#108_00B1" title="Section 108.00 - Subsection B1">108.00B1</a>) that requires the use of the other upper extremity; or
                        </p>
                        <p id="108_09B3">
                            3. Inability to stand up from a seated position and maintain an upright position to the extent needed to independently initiate, sustain, and complete age-appropriate activities due to chronic skin lesions 
                            (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting at least two extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region); or
                        </p>
                        <p id="108_09B4">
                            4. Inability to maintain an upright position while standing or walking to the extent needed to independently initiate, sustain, and complete age-appropriate activities due to chronic skin lesions 
                            (see <a href="#108_00B2" title="Section 108.00 - Subsection B2">108.00B2</a>) or contractures (see <a href="#108_00B3" title="Section 108.00 - Subsection B3">108.00B3</a>) affecting both lower extremities 
                            (including when the limitations are due to involvement of the perineum or the inguinal region).
                        </p>

                        <p>
                            <b>
                                <a href="#Top" class="seventypercent">
                                    <br>
                                    Back to Top
                                </a>
                            </b>
                        </p>

                    </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt on" href="#" title="Back to Top"></a>




</body></html>